Global Alzheimer's Drugs Market 2014-2018

アルツハイマー治療薬のグローバル市場(2014-2018)

◆タイトル:Global Alzheimer's Drugs Market 2014-2018
◆商品コード:IRTNTR3675
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年6月20日
◆ページ数:108
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"アルツハイマー治療薬のグローバル市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Alzheimer’s Disease
Alzheimer’s disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.
TechNavio’s analysts forecast the Global Alzheimer’s Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Alzheimer’s Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer’s disease.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer’s Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Alzheimer’s Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer’s Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Eisai Co., Ltd.
• Forest Laboratories Inc.
• Janssen Pharmaceuticals Inc.
• Novartis AG
Other Prominent Vendors
• Adamas Pharmaceuticals Inc.
• Archer Pharmaceuticals Inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• FORUM Pharmaceuticals Inc.
• H. Lundbeck A/S
• Merck & Co., Inc.
• MorphoSys AG
• Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc.
• Takeda Pharmaceutical Co., Ltd.
• TauRx Pharmaceuticals Ltd.
• Zinfandel Pharmaceuticals Inc.
Key Market Driver
• Increasing Aging Population
• For a full, detailed list, view our report
Key Market Challenge
• Poor Diagnosis of Alzheimer’s Disease
• For a full, detailed list, view our report
Key Market Trend
• Increasing Incidence, Prevalence, and Mortality of Alzheimer’s Disease
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Dementia
06.2 Epidemiology & Forecast (2013-2018)
06.3 Types of Dementia
07. Alzheimer’s Disease
07.1 A Global Burden
07.2 Etiology
07.3 Cost of Care
07.4 Alzheimer’s Disease & Caregiving
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by MOA
09.1.1 AChE Inhibitors
09.1.2 Glutamate Inhibitors
10. Market Assessment of Top Drugs
10.1 Aricept
10.1.1 Sales
10.1.2 Key Regulatory Approvals and Agreements
10.1.3 US Spending by Various Channels 2010-2013
10.2 Exelon
10.2.1 Sales
10.2.2 Key Regulatory Approvals and Agreements
10.2.3 US Spending by Various Channels 2010-2013
10.3 Namenda
10.3.1 Sales
10.3.2 Key Regulatory Approvals and Agreements
10.3.3 US Spending by Various Channels 2010-2013
10.4 Radazyne
10.4.1 Sales
10.4.2 Key Regulatory Approvals and Agreements
11. Competitive Assessment of Top Drugs
12. Focus on Alzheimer’s Research
12.1 National Alzheimer’s Project Act
12.2 Clinical Pipeline
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.2 Market Share Analysis 2013
22. Future Vendors Expected To Tap the Market
23. Key Vendor Analysis
23.1 Eisai Co., Ltd.
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Sales by Geography
23.1.4 Revenue Comparison
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.1.9 Strengths
23.1.10 Weaknesses
23.1.11 Opportunities
23.1.12 Threats
23.2 Forest Laboratories Inc.
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business/Product Segmentation
23.2.4 Product Segmentation by Revenue 2013
23.2.5 Business/Products Segmentation by Revenue 2012 and 2013
23.2.6 Sales by Geography
23.2.7 Business Strategy
23.2.8 Key Information
23.2.9 SWOT Analysis
23.2.10 Strengths
23.2.11 Weaknesses
23.2.12 Opportunities
23.2.13 Threats
23.3 Janssen Pharmaceuticals Inc.
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Product Segmentation
23.3.4 Business Strategy
23.3.5 Key Information
23.3.6 SWOT Analysis
23.3.7 Strengths
23.3.8 Weaknesses
23.3.9 Opportunities
23.3.10 Threats
23.4 Novartis AG
23.4.1 Key Facts
23.4.2 Business Description
23.4.3 Business Segmentation
23.4.4 Revenue by Business Segmentation
23.4.5 Revenue Comparison 2012 and 2013
23.4.6 Sales by Geography
23.4.7 Business Strategy
23.4.8 Key Developments
23.4.9 SWOT Analysis
23.4.10 Strengths
23.4.11 Weaknesses
23.4.12 Opportunities
23.4.13 Threats
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Projected Prevalence of Dementia by Regions 2013-2050 (in millions)
Exhibit 3: Projected Prevalence of Dementia by Regions 2013-2018 (in millions)
Exhibit 4: Types of Dementia by Prevalence 2013
Exhibit 5: Alzheimer’s Disease and Other Dementias Burden by Geographical Segmentation (Annually) 2013
Exhibit 6: Costs of Care by Payer for Americans Age 65 and Older with Alzheimer‘s Disease and Other Dementias 2013
Exhibit 7: Distribution of Alzheimer’s Caregivers by Age, 2013
Exhibit 8: Projected Prevalence of dependence in 2030 (in percent)
Exhibit 9: Global Alzheimer’s Disease Drugs Market 2013-2018 (US$ billion)
Exhibit 10: Global Alzheimer’s Drugs Market Segmentation by MOA
Exhibit 11: Eisai Co. Ltd.’s Aricept Revenue FY1996-FY2013 (US$ million)
Exhibit 12: Eisai Co. Ltd.’s Aricept Geography-wise Revenue FY1996-FY2010 (US$ million)
Exhibit 13: Eisai Co. Ltd.’s Aricept Geography-wise Revenue FY2011-FY2013 (US$ million)
Exhibit 14: Key Event Timeline of Aricept Formulations
Exhibit 15: Timeline for Aricept Formulations in US and Europe
Exhibit 16: US Spending on Aricept by Various Channels 2010-2013
Exhibit 17: Novartis AG’s Exelon Revenue 2001-2013 (US$ million)
Exhibit 18: Novartis AG’s Exelon Geography-Wise Revenue 2001-2013 (US$ million)
Exhibit 19: Key Event Timeline of Exelon Formulations
Exhibit 20: US Spending on Exelon by Various Channels 2010-2013
Exhibit 21: Forest’s Namenda Revenue 2004-2014 (FY ending March 2014) (US$ million)
Exhibit 22: Key Event Timeline of Namenda Formulations
Exhibit 23: US Spending on Namenda by Various Channels 2010-2013
Exhibit 24: Razadyne Revenue 2007-2009 (US$ million)
Exhibit 25: Key Event Timeline of Razadyne
Exhibit 26: Sales of Top 3 Alzheimer’s Drugs FY 2004-2013 (US$ million)
Exhibit 27: Sales of Top 3 Alzheimer’s Drugs 2004-2013 (US$ million)
Exhibit 28: Alzheimer’s Disease Research Projects by NIH Institutes and Centers 2011
Exhibit 29: NIH funded Alzheimer’s Disease Research Projects by CADRO topic 2011
Exhibit 30: Classification of Disease Modifying Pipeline Molecules by MOA
Exhibit 31: Clinical Trials of Alzheimer’s Disease by Phase 2013
Exhibit 32: Clinical Trials of Alzheimer’s Disease by Recruitment Status 2013
Exhibit 33: Promising Late Stage Pipeline Molecules 2013
Exhibit 34: Global Alzheimer’s Drugs market by Geographical Segmentation 2013
Exhibit 35: 65+ Global Population 2014-2018 (in million)
Exhibit 36: Global Alzheimer’s Drugs Market Share Analysis 2013
Exhibit 37: Eisai Co., Ltd.: Geographical Segmentation of Revenue for 2013 and 2012(US$ billion)
Exhibit 38: Eisai Co., Ltd.: Revenue comparison for the last 3 years (US$ billion)
Exhibit 39: Eisai Co., Ltd.: Sales by Geography for 2013 (US$ billion)
Exhibit 40: Forest Laboratories Inc.: Product Segmentation (by therapeutic areas) 2013
Exhibit 41: Forest Laboratories Inc.: Product Segmentation by Revenue 2013
Exhibit 42: Forest Laboratories Inc.: Product Segmentation by Revenue 2012 and 2013(US$ million)
Exhibit 43: Company Name: Sales by Geography 2013
Exhibit 44: Janssen Pharmaceuticals, Inc.: Product Segmentation 2013
Exhibit 45: Novartis AG: Business Segmentation
Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013



【掲載企業】

Eisai Co., Ltd., Forest Laboratories Inc., Janssen Pharmaceuticals Inc., Novartis AG, Adamas Pharmaceuticals Inc., Archer Pharmaceuticals Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Merck & Co., Inc., MorphoSys AG, Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc., Takeda Pharmaceutical Co., Ltd., TauRx Pharmaceuticals Ltd., Zinfandel Pharmaceuticals Inc.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[アルツハイマー治療薬のグローバル市場(2014-2018)] (Global Alzheimer's Drugs Market 2014-2018 / IRTNTR3675)販売に関する免責事項
[アルツハイマー治療薬のグローバル市場(2014-2018)] (Global Alzheimer's Drugs Market 2014-2018 / IRTNTR3675)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆